Magle Chemoswed is a Swedish Contract Development and Manufacturing Organization (CDMO) located in Malm, specializing in the pharmaceutical and medical device industries. Established in 2017 through the merger of Chemoswed AB and Magle Life Sciences, the company combines decades of manufacturing experience with innovative drug development expertise. It employs around 70 professionals who focus on creativity, collaboration, and quality.

The company offers a wide range of services, including analytical development, process development, and manufacturing. It operates a fully cGMP and ISO 13485 certified production site with dedicated manufacturing suites. Magle Chemoswed also provides specialized support for inhalation drug administration and small-scale vial filling and finishing services. In addition to its CDMO services, the company develops and manufactures its own medical technology products using a proprietary technology platform based on starch microspheres. Its client base includes start-ups and major multinational corporations, highlighting its collaborative approach and strong track record in the industry.